Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2...

Related Keywords

United States ,Austria ,Vienna ,Wien ,American ,Yusri Elsayed ,Ajayk Nooka ,European Organization For Research ,Janssen Biotech Inc ,American Society Of Clinical Oncology ,European Commission ,European Hematology Association ,Drug Administration ,Oncology At Emory School Of Medicine ,Janssen Research Development ,Janssen Pharmaceutical Companies Of Johnson ,European Medicines Agency ,New England Journal ,Janssen Pharmaceutical Companies ,Clinical Oncology ,Triple Class Exposed Multiple Myeloma ,Confidence Interval ,Associate Professor ,Medical Oncology ,Emory School ,Prior Exposure ,Patient Reported Health Related Quality ,European Organization ,Cancer Quality ,Life Questionnaire Core ,Studies Investigate ,Vice President ,Disease Area Leader ,Hematologic Malignancies ,Janssen Research ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Biologics License Application ,Janssen Biotech ,Janssen Pharmaceutical Companies Of Johnson Amp ,